Maspin, a member of the serine protease inhibitor (serpin) family, is a tumor suppressor in breast and prostate cancer. To address molecular mechanisms underlying maspin's activity, we restored its expression in invasive carcinoma cells and analyzed the resulting changes by shotgun proteomics. Using a mass spectrometry-based multidimensional proteomic method, we observed changes to the expression of ~27% of the detectable proteome. In particular, we noted changes to the expression of proteins that regulate cytoskeletal architecture, cell death, and protein turnover. In each case, changes in protein expression were accompanied by measurable changes in tumor cell phenotype. Thus, maspin-expressing cells exhibit a more prominent actin cytoskeleton, a reduced invasive capacity, an increased rate of spontaneous apoptosis, and an altered proteasome function. These observations reveal for the first time the far reaching effects of maspin on multiple protein networks and a new hypothesis of maspin function based on the regulation of proteasome function.
inhibitor (serpin) superfamily, like plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2) and α1-antitrypsin (7) . The homology of maspin to serpins led to the hypothesis that its tumor suppressor function might be attributed to its ability to inhibit proteolysis. This idea is supported by the fact that maspin was reported to inhibit the activity of tissue-type plasminogen activator (tPA) (8) and the observation that maspin can mediate the inhibition of urokinase-type plasminogen activator (uPA) on the surface of prostate carcinoma cells (9) .
Despite these studies, other work argues that maspin lacks classical serpin activity. For example, maspin fails to undergo a "stressed to relaxed" conformational transition that is characteristic of virtually all serpins (10) . In addition, a highly rigorous study showed that maspin lacks the ability to inhibit either tPA or uPA, two of its presumed targets, under conditions in which the activity of these proteases can be verified by their ability to activate plasminogen (11). Even though maspin may lack the ability to inhibit serine proteases, its biological function can be attributed to the reactive loop. Recent work shows that subsitution of maspin's reactive site loop into ovalbumin endows that protein with proadhesive and antiinvasive function (12) . Moreover, the loop appears to mediate binding to a cell surface receptor, that ultimately promotes cell adhesion to type I collagen and fibronectin. Other functions for maspin cannot be excluded especially because histologic analysis of maspin shows prominent nuclear and cytoplasmic staining (13, 14) . These observations indicate that maspin could have functions that are therefore unappreciated.
To gain insight into the molecular mechanisms of maspin's tumor suppressor function, we assessed the nature and scope of maspin's effects on the tumor cell proteome. This was done through shotgun proteomics, using multidimensional protein identification technology (MudPIT), which couples tandem mass spectrometry with multiple liquid chromatography steps (15) . Surprisingly this analysis revealed that the expression of maspin has widespread effects on the tumor cell proteome. The effects are observed in nearly one quarter of the detectable proteome and span multiple functional categories. In most cases, protein expression was affected without changes in mRNA levels, indicating that maspin has a significant influence on posttranscriptional regulation of protein levels. This observation is probably a result of maspin's effects on the expression and activity of the proteasome, which may be central to maspin's tumor suppressor activity.
MATERIALS AND METHODS

Tissue culture
The MDA-MB 435 cell line was obtained from Dr. Jane E. Price of the M.D. Anderson Cancer Center, Houston, TX. Tissue culture reagents were purchased from Invitrogen Life Technologies (Carlsbad, CA) unless specified. The cells were maintained in minimal Eagle's media (MEM) Earl's salts, 2 mM L-glutamine, MEM vitamins, nonessential amino acids, and antibiotics (Omega Scientific, Tarzana, CA). Maspin-transfected cells were maintained in the same media with addition of G418 neomycin.
Establishing stable maspin-transfected MDA-MB 435 cells
Maspin cDNA was PCR amplified from total RNA extracted from human mammary epithelial cells and cloned into a mammalian expression vector, pCDNA3 (Invitrogen Life Technologies). The resulting construct was used to transfect MDA-MB-435 breast cancer cell using the DOTAP reagent (Roche, Indianapolis, IN). Stable maspin MDA-MB-435 transfectants were selected by 800 µg/ml G418, and the expression of maspin was confirmed by both PCR and Western blot. Positive clones were maintained in MEM media plus 400 µg/ml G418.
Matrigel invasion assay
The matrigel invasion assay was performed according to the manufacturer's protocol (BD Bioscience, San Jose, CA). Briefly, parent, mock-transfected, and maspin-transfected MDA-MB 435 cells were grown overnight into serum-free media containing 0.1% BSA. The next day, cells were harvested with Versene (0.5 mM EDTA in PBS), resuspended into serum-free MEM media containing 0.1% BSA, and plated in the top compartment of an invasion chamber (BD Bioscience) with a 0.8 µm pore membrane coated with matrigel. MEM media with 5% fetal bovine serum (FBS) was added to the lower chamber, and the cells were allowed to invade through matrigel overnight at 37°C. The next day, the membranes were recovered, fixed, and stained with DiffQuick (IMEB, San Marcos, CA). Cells that had invaded through matrigel were counted at the underside of the membrane in ×20 high-power fields. Triplicates of each cell line were seeded for each invasion experiment, and two independent experiments were performed. The results represent average numbers of two experiments.
SCID mouse model of metastasis
The model of spontaneous metastasis used here was modified from the model originally described by Price et al. (16) . Briefly, female SCID mice aged 5-6 wk (The Jackson Laboratories, Bar Harbor, ME) were anesthetized with ketamine (50 mg/kg) in xylazine administered i.m. Tumor cells were injected into the surgically exposed second mammary fat pad (m.f.p.) of the animal's left side (5×10 5 cells in 50 µl of Hank's balanced salt solution) using a 0.5 ml insulin syringe. Incisions were closed with surgical staples. Tumors were palpable 2 wk after injection into the m.f.p. Primary tumors were allowed to grow for 8 wk, when they were surgically removed under anesthesia. Metastases in lungs were evident 4-5 wk later and were quantified (see below).
Quantification of tumorigenicity and metastasis
After careful excision, primary tumors were weighed. Lungs were fixed in Bouin's solution, and the number of macroscopic metastases was assessed by counting nodules at the surface of the lung under a dissecting microscope. For consistency, the upper right lobe of each lung was used for quantification. In all cases, this lobe represented metastases to the whole lung.
Fractionation and digestion of proteins
Three cell lines, MDA-MB-435 and two stable maspin MDA-MB-435 transfectants (M27 and M59) were seeded at the same cell density in five 150-mm tissue culture dishes per cell line, and the cell pellets were harvested when the cells reached ~80% confluency. From each cell line,
5×10
6 cells were used for each set of MudPIT analysis. Two sets of sample preparation were made in duplicates. In the first set of sample preparation, cell pellets were suspended in 100 µl of 10 mM Tris, pH 8.0, and incubated on ice for 1 h. Then, cells were spun down and the supernatant was transferred to a fresh microcentrifuge tube (soluble fraction). The cell pellets were resuspended in 100 µl of 0.1 M NaCO 3 , pH 11.0, and incubated on ice for 1 h (insoluble fraction). Solid urea was added to 8 M. Proteins were reduced with 5 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP, Roche Applied Science, Palo Alto, CA) and alkylated with 20 mM iodoacetamide (IAM, Sigma, St. Louis, MO). Proteins were digested either following the trypsin protocol (15) or the high pH proteinase K protocol (17) . In the second set of sample preparation, cell pellets were resuspended in phosphate sucrose buffer and digested with either trypsin or proteinase K (external fraction). Then, the remaining cell pellets were further digested with proteinase K (internal fraction).
Multidimensional chromatography and tandem mass spectrometry
Peptide mixtures were pressure-loaded onto a 250 µm inner diameter (i.d.) fused-silica capillary packed first with 4 cm of 5 µm strong cation exchange material (Partisphere SCX, Whatman, Florham Park, NJ), followed by 2 cm of 5 µm C18 reverse phase (RP) particles (Aqua, Phenomenex or Polaris 2000, Varian, Palo Alto, CA). Loaded and washed microcapillaries were connected via a 2 µm filtered union (UpChurch Scientific, Oak Harbor, WA) to a 100 µm i.d. column, which had been pulled to a 5 µm i.d. tip using a P-2000 CO 2 laser puller (Sutter Instruments, Novato, CA), then packed with 10 cm of RP particles and equilibrated in 5% acetonitrile and 0.1% formic acid (buffer A). This split-column was then installed in-line with a Quaternary Agilent (Foster City, CA) 1100 series HPLC pump. Overflow tubing was used to decrease the flow rate from 0.1 ml/min to ~200-300 nl/min. Fully automated 12-step chromatography runs were carried out. Three different elution buffers were used: 5% acetonitrile and 0.1% formic acid (buffer A); 80% acetonitrile and 0.1% formic acid (buffer B); and 0.5 M ammonium acetate, 5% acetonitrile, and 0.1% formic acid (buffer C). In such sequences of chromatographic events, peptides are sequentially eluted from the SCX resin to the RP resin by increasing salt steps (increase in buffer C concentration), followed by organic gradients (increase in buffer B concentration). The last chromatography step consists of a high-salt wash with 100% buffer C followed by acetonitrile gradient. The application of a 2.5 kV distal voltage electrosprayed the eluting peptides directly into an LCQ-Deca ion trap mass spectrometer equipped with a nano-LC electrospray ionization source (ThermoFinnigan, San Jose, CA). Full MS spectra were recorded on the peptides over a 400-1600 m/z range, followed by three tandem mass (MS/MS) events sequentially generated in a data-dependent manner on the first, second, and third most intense ions selected from the full MS spectrum (at 35% collision energy). Mass spectrometer scan functions and HPLC solvent gradients were controlled by the Xcalibur data system (ThermoFinnigan).
Interpretation of MS/MS datasets
PEP_PROBE (18) was used to match MS/MS spectra to peptides in a database containing human sequences downloaded from NCBI on March 2, 2004 . PEP_PROBE is a modified version of SEQUEST (19) and uses a hypergeometric probability model to calculate the confidence for a match to be nonrandom. The validity of peptide/spectrum matches was hence assessed using the SEQUEST-defined parameters, cross-correlation score (XCorr), and normalized difference in cross-correlation scores (DeltaCn), as well as the PEP_PROBE-defined parameters, probability and confidence for a match to be nonrandom. Spectra/peptide matches were only retained if they had a DeltaCn of at least 0.08 and minimum XCorr of 1.8 for +1, 2.5 for +2, and 3.5 for +3 spectra. An 85% confidence for the peptide/spectrum matches not to be random (as defined by PEP_PROBE) was used as cut-off. In addition, the minimum sequence length was seven amino acid residues. DTASelect (20) was used to select and sort peptide/spectrum matches passing this criteria set. Peptide hits from multiple runs were compared using CONTRAST (20) . Proteins were considered detected if they were identified by at least three spectra passing all of the selection criteria or with at least 10% sequence coverage. To generate a dendrogram, an arbitrary minimum value was used to represent the relative protein abundance when the protein was not detectable in the cell line.
Western blot analysis
Whole cell protein extracts were prepared using TotalProteinExtraction kit (Biochain, Hayward, CA), and protein concentration was determined by BCA assay from Pierce (Rockford, IL). Total cell lysate (50 µg) from each cell line were then used to compare protein expression. Immunoblottting assays were carried out by standard procedures using commercially available antibodies (see supplementary material for detailed list). Anti-β-actin antibody (Sigma-Aldrich Corp., St. Louis, MO) was used for equal loading control. Bands were detected using horseradish peroxidase-labeled secondary antibodies and enhanced chemiluminescence detection kit (Amersham Pharmacia, Piscataway, NJ).
Real-time quantitative PCR
Changes in the expression of 56 target genes were examined with real-time PCR (Roche Diagnostic Corporation). The full-length cDNA sequences for genes of interest were obtained from the National Library of Medicine (http://www.ncbi.nlm.nih.gov/UniGene/). Primers were designed to amplify the human target genes using a web-based software (http://www.genome.wi.mit.edu/cgibin/primer/primer3_www.cgi), and then purchased from Integrated DNA Technologies (Coralville, IA). RNA (5 µg) from each tested sample were reverse-transcribed with Superscript II reverse transcriptase (Invitrogen Life Technologies, Carlsbad, CA). The resulting cDNA was diluted 20-fold before PCR amplification. Real-time PCR was performed using a LightCycler (Roche Applied Science, Palo Alto, CA). Reactions were performed using LightCycler-DNA Master SYBR Green I mix (Roche Applied Science). A typical protocol involved a 30 s denaturation step at 95°C, 40 cycles with annealing at 55°C for 5 s and extension at 72°C for 5 s. An automated melting curve analysis was used to verify that all primers yielded a single PCR product.
Fluorescent staining of actin filaments
Cells were grown on Lab-Teck glass chamber slides (Fisher Scientific, Pittsburgh, PA) the day before the experiment. The next day, cells were rinsed once with the serum-free media and fixed in 4% formaldehyde (freshly prepared from p-formaldehyde) in 1× PBS, pH 7.3, for 15 min at room temperature.
Fixed cells were washed a few times in 1× PBS and permeabilized in 0.1% Triton X-100 in the same buffer for 7 min, at room temperature, washed again with 1× PBS, and incubated with Alexa Fluor 594 phalloidin (1:100) (Molecular Probes, Eugene, OR). Stained samples were washed in 1× PBS to eliminate unbound fluorecent conjugates, infused with VectoShield antifadding media (Vector Laboratories, Burlingame, CA), coverslipped and sealed with CytoSeal 60 (Fisher Scientific). Specimens were studied under inverted microscope Nikon TE300, with 60×, N.A. 1.4, oil immersion objective lens and Texas Red/Cy3,5 epi-fluorescent cube (Chroma Technology, Rockingham, VT).
Apoptosis and cell proliferation assays
Spontaneous apoptosis in all cell lines was measured using a Cell Death Detection ELISA PLUS assay (Roche Applied Science). This is a photometric enzyme-immunoassay to detect and quantitate cytoplasmic histone-associated-DNA-fragments (mono-and oligonucleosomes). Cell proliferation in all cell lines was measured using a Cell Proliferation ELISA, which measures the BrdU incorporation over time (Roche Applied Science). All procedures were performed according to the manufacturer's instructions. Briefly, sample cells were trypsinized, resuspended in culture media, and seeded in triplicate wells (1×10 4 cells/well) in 96-well tissue culture plates. Cells were incubated at 37°C and 5% CO 2 for 4 days before measuring apoptosis and proliferation. For the cell death assay, cells were resuspended in 200 µl lysis buffer following by 30 min incubation at room temperature. After incubation, 20 µl of lysate from each well were transferred to the streptavidin-coated microtiter plate. 80 µl of immunoreagent were added to each well, and the plate was incubated for 2 h at room temperature with gentle shaking (~300 rpm). Next, the plate was washed three times with the incubation buffer before the addition of the ABTS solution, and the extent of apoptosis was measured by absorbance at 405 nm in a microplate reader. Each experiment was repeated twice to confirm the trend, and one set of the representative data was presented in the result section.
For the cell proliferation assay, the media was replaced with the BrdU labeling media 16 h before the analysis of cell proliferation. After BrdU labeling, FixDenat solution was added to the cells and removed after 30 min incubation at room temperature. Then antiBrdU POD was added to each well and incubated for 30-120 min at room temperature before the addition of the substrate solution. Once the desired intensity of color was developed, the reaction was stopped by 1 M H 2 SO 4 solution. The absorbance of each well was measured at 450 nm.
Fluorometric 20S proteasome assay
Cells were harvested after four passages in culture and homogenized in the lysis buffer from the Biochain total protein extraction kit (Biochain). Cellular 20S proteasome activity was assayed using a 20S proteasome assay kit (BIOMOL International LP, Plymouth Meeting, PA) according to the manufacturer's standard protocol. Fluorogenic peptide substrates Suc-LLVY-AMC (chymotrypsin activity) and Z-LLE-AMC (PGPH activity) were obtained from Calbiochem (San Diego, CA). Fluorogenic peptide substrate Boc-LRR-AMC (trypsin activity) was obtained from BIOMOL International LP. Briefly, 50 µg of cell lysate were added to 1× reaction buffer diluted from the 20× reaction buffer (500 mM HEPES, 10 mM EDTA, pH 7.6) so that the final reaction volume was 90 µl. Triplicate reactions were set up for each cell lysate. The diluted lysates were incubated at 37°C for 5 min for equilibration at assay temperature. During incubation, 20× substrate solution was made by diluting the fluorogenic peptide substrate stocks in reaction buffer. To each reaction, 10 µl of the appropriate 20× substrate stock solution were added, and the fluorescence activity (ë ex : 380 nm; ë em : 460 nm) was measured in a microplate fluorescence reader (Gemini XPS from Molecular Device, Sunnyvale, CA). Data shown in the result section represented one of the replicate experiments. The final substrate concentration was 10 µM for the chymotrypsin-like and trypsin-like activity assays and 100 µM for the PGPH activity assay. MG-132 (Calbiochem, San Diego, CA), a chymotryptic proteasome inhibitor, was used to show the specificity of the chymotrypsin-like proteolytic activity.
Analysis of high molecular weight ubiquitin-protein conjugates
Cell lysates were generated as described in the Western blot analysis section. Cell lysates were separated in a 10% SDS-PAGE, transferred to a nitrocellulose membrane, and blocked with 5% nonfat milk. A monoclonal anti-ubiquitin antibody (1:100) (EMD Bioscience, San Diego, CA) was incubated with the blot for 2 h at room temperature. Then, the blot was washed three times with wash buffer (PBS+0.05% Tween 20) . A HRP-conjugated anti-mouse (1:10,000) antibody (Bio-Rad, Hercules, CA) and an enhanced chemiluminescence detection kit (GE HealthAmersham Bioscience, Piscataway, NJ) were used to detect the presence of ubiquitin as well as ubiquitin modified proteins.
RESULTS
Proteomic profiling of parental and maspin-transfected carcinoma cells
The anti-metastatic properties of maspin were originally demonstrated in the metastatic MDA-MB 435 mammary carcinoma cells (1) . To address the effects of maspin on the tumor proteome, we recapitulated this system by establishing four stable sublines of the MDA-MB 435 cells that were transfected with maspin cDNA. The expression of maspin was verified for all of the transfected clones (Fig. 1A) . As previously reported, transfection of the MDA-MB 435 cells with maspin reduced cell invasion in vitro and metastatic spread in vivo (Fig. 1B, 1D ). As previously reported by Zou et al. (1), some of the clones transfected with maspin also had reduced tumorigenicity (Fig. 1C , clones M27 and M60). However, reductions in primary tumor growth do not appear to be necessary for reductions in metastasis because all maspin-transfected clones showed nearly complete ablation of metastasis in vivo. We were most interested in identifying changes linked to reductions in metastatic spread, so we chose to compare protein expression in the parental MDA-MB 435 cells with that of the M27 and M59 lines. We expected this comparison to reveal changes common to the nonmetastatic phenotype, without bias toward proteins mechanistically involved in altering tumorigenicity.
The MDA-MB 435 cells and the M27 and M59 lines were subjected to MudPIT analysis. In total, we detected 30,000 peptides that corresponded to 2315 different proteins (Table 1 , supplementary material). To obtain a semiquantitative comparison of protein expression levels, we used two parameters: the number of spectra collected per protein (spectra count) (21) and the percentage of protein sequence covered by detected peptides (sequence coverage) (22) . To minimize false positives, the initial list of 2315 proteins was filtered to eliminate proteins that were identified by fewer than three spectra or <10% sequence coverage. These filters produced a list of 1124 proteins for further analysis (Fig. 1, supplementary material) . We compared the expression of each protein on this list in the M27, the M59, and parental MDA-MB 435 cells. An expression ratio of 1.5-fold was arbitrarily set as a threshold for significance. Using this criterion, we found 113 proteins to be up-regulated and 185 proteins to be down-regulated in both of the maspin-transfected cell lines. Based on these values, maspin led to alterations in the expression level of ~27% of the detected proteome.
Independent approaches were used to validate the changes in protein levels indicated by MudPIT analysis. Based on known relevance to cancer biology and the availability of antibodies, we chose 22 differentially expressed proteins for analysis by Western blot. The direction of the change in protein expression observed by Western blot correlated exceptionally well with MudPIT analysis. Twenty out of 22 proteins exhibited altered expression in the direction indicated by the differential proteomic analysis ( Fig. 2A, 2B ).
In addition, we compared the mRNA level of 55 candidate proteins to determine if changes in protein expression could be attributed to changes in gene transcription (Table 1) . Interestingly, only 17 of 55 genes exhibited changes that mirrored the alterations in protein levels. Therefore, maspin elicits changes to both gene and protein expression levels, but the majority of changes detected in this study can be attributed to posttranscriptonal regulation of protein expression.
Maspin expression affects proteins of the actin cytoskeleton network
Using the web-based data analysis software, Genesifter (www.GeneSifter.net), we clustered the proteomic dataset based on the Gene Ontology (GO) classification. From this analysis we recognized that maspin expression affected three protein networks that are crucial in tumor progression and metastasis: cytoskeleton organization, apoptosis, and protein turnover.
In maspin-transfected cells, considerable changes in the expression of proteins linked to cytoskeletal organization were detected (Fig. 3A) . Changes to several of the proteins were confirmed by Western blot (Fig. 2A, 2B ,) see α-actin, plectin 1, actinin-4, caldesmon 1, and profilin 1). Immunostaining of the maspin-expressing cells revealed parallel and thick actin filaments, which were different from the parental and mocked-transfected MDA-MB 435 cells (Fig. 3B) . The actin filaments of the maspin transfectants resemble that of nonmigratory cells, whereas the thinner and less dense actin cables of the parental cells (Fig. 3B ) are more consistent with migratory cells. These observations are generally consistent with results from the proteomic analysis, where proteins known to restrict cell migration are up-regulated in the maspintransfected cells (e.g., α actinin-4, tropomyosin 1, caldesmon 1, coronin, desmuslin), while proteins known to promote cell migration were down-regulated in response to maspin expression (e.g., actin-related protein, α-tubulin, leupaxin, F-actin capping protein). These results are consistent with maspin's antiinvasive activity.
Maspin expression increases the spontaneous apoptosis in carcinoma cells
Proteins involved in apoptosis were also affected by maspin. Differential proteomic analysis showed that proteins known to promote apoptosis were up-regulated in maspin-expressing cells (e.g., reticulon 4, tyrosyl tRNA ligase, Acinus, SON DNA binding protein), while antiapoptotic proteins were down-regulated (e.g., α-synuclein, secreted phosphoprotein 1) (Fig. 4A ). In agreement with these changes, we found an increased rate of spontaneous cell death in all four maspin-transfected clones compared with the parental or mock-transfected MDA-MB 435 cells (Fig. 4B) . No significant differences in the rate of proliferation were observed (Fig. 4B ). This proapoptotic phenotype may contribute to the reduced metastatic behavior of maspin-transfected cells in vivo.
Maspin expression inversely correlates with the chymotrypsin-like activity of the 26S proteasome
Most of the changes elicited by maspin on protein expression appear to be regulated at the posttranscriptional level, and our differential proteomic analysis revealed changes to important components in the ubiquitin-proteasome system (Fig. 5A) . Therefore, we performed a more comprehensive analysis of this protein network. First, we compared the activity level of the proteasome in maspin transfectants. The 20S proteasome has three major proteolytic activities: a chymotrypsin-like, a trypsin-like, and a peptidylglutamylpeptide hydrolyzing activity (PGPH) (23, 24, 25) . Each of these can be assessed in cell lysates using fluorescent substrates that reflect their catalytic specificity (26, 27). We found the trypsin-like and PGPH catalytic activities are essentially identical in the maspin transfectants and the parental MDA-MB 435 cells (data not shown). However, maspin-expressing cells showed reduced chymotrypsin-like activity compared with the parental and mock-transfected cells (Fig. 5B) . The β5 subunit of the proteasome plays a crucial role in chymotrypsin-like activity of proteasome (28), but it was not detected in the MudPIT analyses perhaps due to its low abundance. Therefore, we compared its protein level among the parental and maspin-transfected MDA-MB 435 cells using Western blot. Indeed, we found that the β5 subunit was down-regulated in all maspin-transfected cells compared with the parent cells (Fig. 5C) . Consequently, reduced chymotrypsin-like activity observed in maspintransfected cells can partly be attributed to down-regulation of β5 subunit of the proteasome.
In concert with the reduced chymotrypsin-like activity of the proteasome, we also found accumulation of high molecular weight ubiquitin-protein conjugates in maspin-transfected cells (Fig. 5D ). This accumulation may result from an overall reduction in proteasome activity. The different catalytic sites of the proteasome act in a hierarchical manner (29), with the chymotrypsin-like activity normally determining the rate of protein breakdown (23) . Thus, a reduction in chymotryptic activity is likely to change the regulation of protein turnover in maspin-expressing cells. Recent work showed that reductions in overall proteasome activity can lead to the accumulation of high molecular weight ubiquitin conjugates (30). Consequently, our results suggest an inverse correlation between the expression of maspin and proteasome activity.
DISCUSSION
It is not entirely clear whether maspin's tumor suppressor activity is a result of its function as a protease inhibitor (8, 9) or as a ligand for some cell surface receptor (12), or both. This study was an attempt to jump downstream of these points of mediation and understand the biochemical basis for maspin's effects on tumor phenotype. To accomplish this, we used shotgun proteomics to compare the proteomes of maspin-deficient and maspin-expressing tumor cells. The general conclusions of this study are 1) the effects of maspin on the tumor cell proteome are widespread, with changes in expression evident in about one quarter of all detected proteins; 2) maspin elicits changes in the expression of proteins associated with the actin cytoskeleton that predict a less motile and invasive phenotype, a finding that is consistent with the less invasive phenotype of maspin in vitro, and reduced metastatic spread in vivo; 3) maspin is correlated with changes to proteins associated with apoptosis that predict a greater sensitivity to cell death, a phenotype that is consistent with a higher rate of spontaneous apoptosis of maspin-expressing tumor cells, and that may contribute to the inability of maspin-expressing cells to metastasize; 4) maspin appears to have an effect on the ubiquitin-proteasome pathway, indicating that the proteasome could be a key downstream regulator of tumor progression; and 5) MudPIT is capable of providing highfidelity comparisons of relative protein expression, which, in the vast majority of cases, can be confirmed by Western blotting.
Importantly, the expression level of maspin in each transfected cell line appears to exceed the threshold for a complete biological response. While there are variations in maspin levels among the four transfected clones, their invasiveness in vitro and metastatic spread in vivo is essentially ablated in all of the clones (Fig. 1) . Similarly, even though the level of chymotryptic proteasome activity in each transfected line is reduced compared with controls, there are no substantive differences in this activity among the maspin-transfected lines (Fig. 5B) . Together, these bioassays indicate that the system used in this study is suitable for identifying trends in protein expression correlated to maspin and its antimetastatic effects. However, the system is probably not suitable for testing for correlations between changes to a proteins expression vs. a "dose response" of maspin. With this limitation in mind, several correlations that we identified are worthy of further discussion.
One hallmark of malignant transformation is the enhanced motility of cancer cells and their invasion into normal tissues (31). The actin network and its associated proteins are necessary to support this enhanced migratory ability of invasive cancer cells. Our results show that maspin causes significant alterations in proteins associated with the actin network. In most cases the changes in these cytoskeletal proteins are predicted to result in a reduction in cell motility. For example, epithelial protein lost in neoplasm (EPLIN) is a member of cytoskeleton-associated proteins that was found up-regulated in maspin-transfected breast cancer cells. EPLIN has been shown to be down-regulated in transformed cells (32, 33). It promotes the formation of stable actin filament structures such as stress fibers at the expense of more dynamic actin filament structures such as membrane ruffles (34). Hence, reduced expression of EPLIN may contribute to the motility of invasive tumor cells. Another example of a cytoskeleton-associated protein that has a profound influence on cell motility is gelsolin. Opposite of EPLIN, gelsolin was found down-regulated in maspin-transfected breast cancer cells. Gelsolin is one of a family of actin binding proteins involved in controlling the organization of the actin cytoskeleton in cells (35). Cells deficient in gelsolin exhibit defective chemotaxis and wound healing (36); conversely, overexpression of gelsolin increases membrane ruffling and chemotaxis (37). These changes are consistent with the fact that maspin-transfected breast cancer cells contain bundles of actin in the form of stress fibers, and exhibit reduced motility, invasiveness, and metastatic potential.
Apoptosis is another critical cellular function that is frequently dysregulated in tumor cells (38) (39) (40) , particularly in those with increasing metastatic propensity (41) . A proapoptotic effect of maspin has been reported by Sheng's group in breast-and prostate cancer cells (42, 43) . They reported that endogenous maspin expression sensitizes breast carcinoma cells to staurosporine (STS)-induced apoptosis in vitro and Bax seems to play an essential role in the proapoptotic effect of maspin. Our data further demonstrate that increased apoptosis plays an important role in maspin function. For example, one of the apoptosis regulatory proteins, protein phosphatase 2 (PP2A), was found up-regulated in maspin-transfected breast cancer cells. Recently it has been shown that ceramide activates protein phosphatase 2 and can regulate apoptosis by a mechanism involving dephosphorylation of the antiapoptotic molecule Bcl2 (44) . The nonphosphorylatable (i.e., PP2A-resistant) gain-of-function S70E mutant Bcl2 can protect cells from ceramideinduced apoptosis (44) . Since ceramide production is a nearly universal component of apoptosis, it is possible that such a mechanism may exit in response to other apoptotic stimuli. Another apoptosis regulatory protein, Acinus, was found up-regulated in maspin-transfected breast cancer cells. Using an in vitro system, Tsujimoto's group showed that Acinus is essential in the induction of apoptotic chromatin condensation in cells after cleavage by caspase-3 without inducing DNA fragmentation (45) . These changes are consistent with our observation that maspin-transfected breast cancer cells show signs of increased spontaneous apoptosis.
The ubiquitin proteasome pathway is a highly conserved intracellular pathway for intracellular protein degradation, and our results strongly suggest that the function of this pathway is influenced by the expression of maspin. In this study, we showed that there is a negative correlation between maspin expression and the chymotrypsin-like activity of the proteasome. The reduction in chymotrypsin-like activity appeared to result from the down-regulation of the β5 subunit of the proteasome in all maspin-transfected cells. This newly found connection raises the interesting possibility that the tumor suppressor function of maspin may be mediated through the proteasome. This idea is supported by three results. First, most of the changes in protein abundance that we detect occur at the post-transcriptional level. Since the proteasome is a major regulator of protein turnover, it stands to reasons that it plays a role in enacting many of the changes in protein abundance that we observe. Second, we also find direct evidence that the abundance of several subunits of the proteasome are altered by maspin, including the β5 subunit (Fig. 5C) , as well as the α6 and α7 subunits (Fig. 6) . Third, we observed that maspin-expressing cells exhibit reductions in the chymotrypsin-like activity of the proteasome (Fig. 5B) . Altogether, these observations indicate that subunit composition and activity of the proteasome are altered in maspin-expressing cells.
Interestingly, there are a number of examples in the literature where changes in subunit composition of the proteasome result in phenotypic changes in cells. For example, proteasomes isolated from different tissues are comprised of different combinations of subunits, and have different activities toward small peptide-based substrates (46, 47) . Changes in proteasome subunit composition and activity are also observed in Drosophila during development (48) where dominant-negative mutations in individual subunits of the proteasome have been shown to regulate cell fate (49) . Perhaps the best known phenotypic change resulting from proteasome subunit switching is the interferon-γ-induced expression of the immunoproteasome, which has a key role in the presentation of antigen peptides by MHC class I molecules (50) . Interestingly, the immunoproteasome has a distinct substrate specificity by substituting three of the proteasome subunits with interferon-γ inducible subunits (51-54). The results presented here show interesting parallels with subunit switching in the case of the immunoproteasome, and suggest the possibility that maspin enacts a change in proteasome composition and activity, which ultimately plays a role in determining the metastatic phenotype.
Maspin could potentially be involved directly or indirectly in the regulation of proteasome activity. To prove an interaction of maspin with the proteasome, we immuno-precitated the 20S and 26S proteasomes with antiproteasome α-subunits (BIOMOL International LP) and anti19S antibodies (EMD Bioscience) but we did not detect maspin in the pulled-down complexes (data not shown). The result indicated either no direction interaction or weak interaction between the proteasome and maspin. Furthermore, we found that maspin expression in breast cancer cells caused the accumulation of high molecular weight ubiquitin-protein conjugates as determined by immunoblotting with ubiquitin-specific antibody (Fig. 5D) . Maspin was detected in the enriched ubiquitinated protein fraction from the cell lysate (data not shown). There was no higher molecular weight maspin detected, suggesting that maspin is probably not ubiquitin-conjugated.
It is known that catalytic properties of the proteasome can vary widely, depending on its association with regulatory proteins (55). An example of this paradigm is inhibition of the proteasome activity by insulin. In HepG2 cells, insulin increases ubiquitin-conjugate protein accumulation by 80% and decreases ubiquitin-mediated proteasomal activity (56). Furthermore, it was shown that the displacement of insulin degradation enzyme (IDE) by insulin from the 20S proteasome provided a mean by which insulin may inhibit the ubiquitin-dependent degrading activity of the 26S proteasome (56). Our preliminary results of maspin and the proteasome regulation seem to resemble the paradigm of reducing the proteasome activity by cofactor displacement such as the insulin and insulin degradation enzyme system described above. Therefore, it raises the possibility of reducing the proteasome activity by displacing a yet unknown proteasome cofactor by maspin.
In summary, proteome analysis provided valuable insights into maspin's antimetastasis mechanism. By investigating the proteome of cancer cells affected by maspin expression, we identified potential molecular pathways for the observed phenotypic changes in maspintransfected cancer cells: structural alterations of actin cytoskeleton, and increased apoptosis. We also revealed an inverse correlation between maspin and 20S proteasome activity. Deregulation in the expression of 20S proteasome subunits seemed to accompany the decreased cellular proteasome activity in the maspin-transfected cancer cells. As we continue to learn about the aberrant regulation of the ubiquitin-proteasome pathway in cancer cells and the resulting changes in its housekeeping functions, we can speculate that alteration in proteasome activity might be a key step toward metastasis. Based on the present study, we speculate that many effects that have been reported about maspin could be attributed to maspin's function in keeping the delicate and specific regulation of the ubiquitin-proteasome pathway, the net result of which could influence metastasis-related events. Although we have only little clues about the detail mechanism of how maspin can modulate proteasome activity directly or indirectly, our data point toward a new hypothesis of the molecular mechanism of maspin, and insinuate a potential contribution of the ubiquitin-proteasome pathway in the regulation of tumor metastasis. expression of β5 proteasome subunit, and increased high molecular weight ubiquitin-protein conjugates. A) A list of proteins associated with the ubiquitin-proteasome pathway found in the proteomic data was presented in an expression boxplot. B) Significant reduction in chymotryptic activity of the 20S proteasome was observed in maspin-transfected cell lysates (see Materials and Methods for details). A proteasome inhibitor targeting the chymotrypsin-like site, MG132, was used to show the specificity of the chymotrypsin-like proteolytic activity in this assay. C) Reduced protein level of β5 proteasome subunit corresponding to the chymotrypsin-like proteolytic activity was found in all maspin transfectants by Western blot. D) As the result of reduced chymotrypsin-like 20S proteasome activity, the accumulation of high molecular weight ubiquitin-protein conjugates was observed in the cell lysate of maspin-transfected comparing to the control MDA-MB 435 cells. The high molecular weight ubiquitin-protein conjugates were detected by an anti-ubiquitin antibody. 
